Palladio Biosciences   Report issue

For profit Phase 3
Founded: Newtown PA United States (2015)
Status: Acquired by Centessa (2021)

Organization Overview

First Clinical Trial
2018
NCT03487913
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Palladio Biosciences

Active Ingredients

Drugs in Phase 3 Trials (1)

lixivaptan (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Kidney Diseases (Phase 3)

Pain, Intractable (Phase 2)

Polycystic Kidney, Autosomal Dominant (Phase 3)

Polycystic Kidney Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 1